1 active not recruiting, 1 completed, 1 recruiting, 1 terminated. 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Active not recruiting 1, Completed 1, Recruiting 1, Terminated 1 |
Follow selexipag: new trials by email Literature Review of selexipag trials Research Report on selexipag
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension Prostacyclin Pathway Agent, Sildenafil Dose Optimization - Pulmonary Arterial Hypertension (PAH) | Phase 4 | Recruiting | University of Sao Paulo General Hospital | 196 | 2026-07-22 | 2026-07-30 |
| Pulmonary Hypertension: Intensification and Personalisation of Combination Rx Selexipag, Riociguat, CardioMEMS pulmonary artery pressure monitor - Pulmonary Arterial Hypertension | Phase 4 | Active not recruiting | Sheffield Teaching Hospitals NHS Foundation Trust | 70 | 2023-06-14 | 2026-08-07 |
| A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging JNJ-67896049 - Pulmonary Arterial Hypertension | Phase 4 | Terminated | Actelion | 9 | 2021-07-07 | 2025-03-30 |
| Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension. Selexipag, Placebo - Pulmonary Arterial Hypertension | Phase 4 | Completed | Actelion | 108 | 2017-11-08 | 2025-03-30 |
Pulmonary Arterial Hypertension (4) · Motor Activity (1)
Actelion (2) · Sheffield Teaching Hospitals NHS Foundation Trust (1) · University of Sao Paulo General Hospital (1)
United Kingdom (3) · Brazil (2) · France (2) · Germany (2) · United States (2) · Argentina (1) · Austria (1) · Hong Kong (1) · Ireland (1) · Israel (1) · Malaysia (1) · Netherlands (1) · Norway (1) · Portugal (1) · Russia (1)
Alexander Rothman, MD / PhD (1) · Caio Fernandes (1) · Thomas Pfister (1)
2019 (1)